Quantcast

Latest Trastuzumab Stories

2011-03-14 14:00:12

UT MD Anderson scientists find adding SRC inhibitor breaks hub of opposition Breast cancer tumors take numerous paths to resist the targeted drug Herceptin, but a single roadblock at a crucial crossroads may restore a tumor's vulnerability to treatment, scientists at The University of Texas MD Anderson Cancer Center report on line at Nature Medicine. Adding the drug saracatinib to Herceptin treatment shrinks previously resistant tumors by cutting off at least five different molecular...

2011-03-08 13:35:45

Combining targeted therapies might be required for maximum anti-tumor activity when treating HER2-positive breast cancers, according to two new studies by Vanderbilt-Ingram Cancer Center (VICC) investigators. The findings, reported in two papers in the Proceedings of the National Academy of Sciences (PNAS), suggest that upregulation of the HER3 receptor limits the effectiveness of two classes of targeted therapies (HER2- and PI3 kinase-targeted therapies). Therefore targeting HER3 together...

2011-03-07 06:00:00

INCLINE VILLAGE, Nev., March 7, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced revenue guidance for the first quarter ending March 31, 2011 of approximately $83 million, as compared with actual results of $62 million for the first quarter of 2010, an expected 34 percent year-over-year increase. Included in first quarter revenue guidance is the $10 million settlement received from UCB Pharma S.A. (UCB) in January 2010 resolving all legal disputes between the...

2011-03-03 16:47:21

Using recent advances in genomics, researchers have uncovered a genetic pathway that affects the development of breast cancer, work that could help predict which patients are at risk of relapse for the disease. By studying which genes are expressed - or "turned on" - in breast cancer, research led by Michigan State University's Eran Andrechek uncovered a role for several members of the E2F family of genes, which control cell division and growth. Specifically, Andrechek's team found the...

2011-03-01 08:49:06

(Ivanhoe Newswire) -- For women with aggressive early-stage breast cancer (HER2-positive disease), trastuzumab (Herceptin) given for one year after chemotherapy proved to put the women at significantly less risk of the cancer returning. The effect is long lasting, according to this study. Around 20% of women with breast cancer have HER2-positive cancer and are at high risk of cancer recurrence and of dying from the disease. Trastuzumab is a monoclonal antibody developed to block the...

2011-02-01 01:51:47

Potential therapeutic targets identified for deadly, untreatable lung disease Researchers at National Jewish Health have discovered a signaling pathway that is crucial to the devastating effects of acute lung injury (ALI). The data, obtained from cells, animals and ALI patients, suggest several potential therapeutic targets. Experimental blockade of one of the targets significantly reduced flooding of the lungs that is the hallmark of ALI. "Acute lung injury is a devastating disease, with 40...

2011-01-31 10:24:00

FREDERICKSBURG, Va., Jan. 31, 2011 /PRNewswire/ -- Research to develop more effective treatments for triple negative breast cancer -- a difficult disease to cure -- could someday benefit all breast cancer patients, reports Dr. Frederick C. Tucker, Jr. of Fredericksburg Oncology. "Understanding how triple negative cancers spread in the absence of normal growth factors may give us insight into how other types of breast cancer grow and spread even after treatment," Dr. Tucker explains....

2011-01-25 08:00:00

WORCESTER, Mass., Jan. 25, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTC Bulletin Board:GNBT), together with its wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, Inc. (www.antigenexpress.com), announced today that it has amended the Clinical Study Agreement with The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (www.hjf.org) in regard to the on-going Phase II clinical study of Antigen's AE37 novel...

2011-01-06 05:00:00

ROCKVILLE, Md., Jan. 6, 2011 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that it had administered drug to the first cohort of patients in a Phase I clinical trial of MGAH22. MGAH22 is an Fc-optimized monoclonal antibody developed by MacroGenics which has been shown, in pre-clinical studies, to reduce tumor growth significantly in a broad panel of...

4eed36960aad25c3ea887154094418b61
2010-12-23 08:02:49

Implications for blocking metastasis and improving responses to existing therapies Overexpression or hyperactivation of ErbB cell-surface receptors drives the growth of many breast cancers. Drugs, like Herceptin, that block the receptors' signals halt tumor progression in some patients. However, not all patients' tumors respond, with some becoming resistant over time. Different drugs that interfere with other steps in the signaling pathway may improve the response of patients, yet little is...


Word of the Day
lambent
  • Licking.
  • Hence Running along or over a surface, as if in the act of licking; flowing over or along; lapping or bathing; softly bright; gleaming.
This word comes the Latin 'lambere,' to lick.
Related